JHDD-cofounded PSMA Therapeutics acquired by Bayer AG
JHDD-developed glutamine antagonist receives Fast Track designation from FDA for small-cell lung cancer
JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]
JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain
Partnership Awards $3 Million In Grants For Promising New Treatments In Alzheimer’s And Related Dementias
Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.